CDA and malignant colon neoplasm: Although decitabine treatment of colon cancer cells repressed DNMT1 protein expression by about 30% (Fig. 8A1), the additional gene knockdown of CDA enhanced decitabine’s ability to promote DNMT1 protein degradation, and depending on the cell line, its expression was reduced between 80 and 90%.